COMMUNIQUÉS West-GlobeNewswire

eLabNext and ABI-LAB Announce Strategic Partnership to Foster Innovation in Life Sciences

26/07/2024 - 17:59

BOSTON, July 26, 2024 (GLOBE NEWSWIRE) -- eLabNext, a leading provider of digital lab management solutions, and ABI-LAB , a premier life sciences incubator located in Natick, MA, have announced a strategic alliance [...]

BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo

26/07/2024 - 17:15

July 26, 2024 News Release BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo ADLM 2024 Conference – Chicago, July 26, 2024 – BioPorto Diagnostics, a company specializing in in vitro [...]

Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab

26/07/2024 - 16:46

SHANGHAI, July 26, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

26/07/2024 - 15:30

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group ") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is [...]

Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency

26/07/2024 - 15:00

Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”) , an artificial intelligence (AI)-powered medical technology [...]

Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting

26/07/2024 - 15:00

Boston (July 26, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, announced that its [...]

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

26/07/2024 - 14:35

Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) [...]

OneMedNet Announces $4.6 Million Private Placement

26/07/2024 - 14:30

Institutional investors include affiliates of Off the Chain Capital and Discovery Capital Management MINNEAPOLIS, July 26, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), [...]

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

26/07/2024 - 14:30

$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approval Fundraise supports development of novel antibody PMN310 [...]

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

26/07/2024 - 14:20

Presentation to feature Silo’s novel therapeutics for the underserved SARASOTA, FL, July 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical [...]

CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy

26/07/2024 - 14:08

Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib 1 ,2,3,4 In the [...]

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

26/07/2024 - 14:01

Scienture, Inc., a private branded and specialty pharmaceutical company, entered into a business combination with TRxADE Health Inc., in an all-stock transaction valued at $103 million. TAMPA, FL and COMMACK, NY, July [...]

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

26/07/2024 - 14:00

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results [...]

Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds

26/07/2024 - 14:00

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise [...]

Genetic Technologies Strategic Restructure Driving USA Sales Growth

26/07/2024 - 14:00

CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent [...]

GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis

26/07/2024 - 13:45

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients [...]

GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive

26/07/2024 - 13:45

Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), 26 juillet 2024 - GENFIT (Nasdaq et Euronext : GNFT) , une société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie [...]

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

26/07/2024 - 13:20

TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]

Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

26/07/2024 - 13:05

If approved, Yuvanci ® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson’s comprehensive PAH portfolio has the potential to cover all guideline-recommended [...]